QV Investors Inc. Has $15.78 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

QV Investors Inc. raised its position in Johnson & Johnson (NYSE:JNJ) by 0.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 97,370 shares of the company’s stock after buying an additional 260 shares during the period. Johnson & Johnson accounts for about 1.4% of QV Investors Inc.’s investment portfolio, making the stock its 29th biggest position. QV Investors Inc.’s holdings in Johnson & Johnson were worth $15,780,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Regatta Capital Group LLC boosted its holdings in shares of Johnson & Johnson by 7.5% in the 3rd quarter. Regatta Capital Group LLC now owns 6,684 shares of the company’s stock worth $1,083,000 after acquiring an additional 468 shares in the last quarter. Petredis Investment Advisors LLC boosted its stake in Johnson & Johnson by 0.3% in the third quarter. Petredis Investment Advisors LLC now owns 38,034 shares of the company’s stock worth $6,164,000 after purchasing an additional 118 shares in the last quarter. Ullmann Wealth Partners Group LLC grew its holdings in shares of Johnson & Johnson by 29.8% during the third quarter. Ullmann Wealth Partners Group LLC now owns 6,292 shares of the company’s stock worth $1,020,000 after purchasing an additional 1,445 shares during the last quarter. Peak Financial Management Inc. acquired a new stake in shares of Johnson & Johnson in the third quarter valued at $231,000. Finally, RDA Financial Network lifted its position in Johnson & Johnson by 1.6% during the 3rd quarter. RDA Financial Network now owns 6,039 shares of the company’s stock worth $979,000 after buying an additional 93 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on JNJ shares. TD Cowen dropped their target price on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research note on Thursday, July 18th. Sanford C. Bernstein boosted their price objective on shares of Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. Daiwa Capital Markets lowered Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Morgan Stanley raised their price target on Johnson & Johnson from $167.00 to $169.00 and gave the company an “equal weight” rating in a report on Thursday, July 18th. Finally, The Goldman Sachs Group cut their target price on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research report on Friday, July 19th. Six analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $174.31.

Johnson & Johnson Trading Up 1.6 %

Shares of NYSE JNJ opened at $164.14 on Wednesday. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85. The stock has a market cap of $395.02 billion, a price-to-earnings ratio of 10.23, a P/E/G ratio of 2.65 and a beta of 0.52. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The company’s fifty day moving average is $162.70 and its 200-day moving average is $154.52.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. The firm had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company’s revenue was up 4.3% on a year-over-year basis. During the same period in the previous year, the firm earned $2.80 earnings per share. Equities research analysts predict that Johnson & Johnson will post 10 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.02%. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.